ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Montréal, QC, CAN:

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Nemtabrutinib
Drug: Acalabrutinib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Montréal, Quebec, Canada and 143 other locations

of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...

Enrolling
Lymphoma, Small Lymphocytic
Leukemia, Chronic Lymphocytic
Drug: Nemtabrutinib
Biological: Rituximab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Greenfield Park, Quebec, Canada and 47 other locations

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Montreal, Quebec, Canada and 86 other locations

Status recently updated

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Montreal, Quebec, Canada and 216 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

Montréal, Quebec, Canada and 48 other locations

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Montreal, Quebec, Canada and 170 other locations

venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Drug: Chlorambucil
Drug: Venetoclax

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 136 other locations

the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Idelalisib

Phase 3

Acerta Pharma
Acerta Pharma

Montreal, Canada and 156 other locations

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Enrolling
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Acute Myeloid Leukemia (AML)
Drug: Zanubrutinib
Drug: PRT2527

Phase 1

Prelude Therapeutics

Montreal, Quebec, Canada and 23 other locations

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Invitation-only
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Ibrutinib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Montreal, Quebec, Canada and 173 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems